Shares of the Covid-19 vaccine maker BioNTech (BNTX.US) skyrocketed during today’s US session after the company released its Q2 results (today, before the opening bell). The company said that it and its partner Pfizer (PFE.US) had shipped roughly 1 billion doses of their coronavirus vaccine as of late July. Both companies have signed orders for delivery of more than 2.2 billion doses this year.
BioNTech earned $12.67 per share on $6.24 billion second-quarter sales. Results topped expectations as Wall Street anticipated earnings of $8.87 per share on $3.83 billion of revenues. The company’s CEO says that currently the best approach is to continue with a booser dose of the existing vaccine, but the situation may also require adaptation of the vaccine amid further variants. Also, the firm hinted at potential M&A plans as well as licensing of products and strategic collaborations in order to boost its pipeline of cancer drugs.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app
BioNTech (BNTX.US) shares have risen more than 100% over the past… month! Earlier the stock was trading in an upward channel, but a breakout followed. At press time the price is soaring 15% and the daily candlestick shows that bulls remain in control during today’s trading. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
